Objectives
In recent years, the pharmaceutical industry has received approval in the US and Europe for several products that are unique, meet previously unmet needs, and yield important reductions in mortality and morbidity. Frequently, these products are oncology, orphan and ultra-orphan drugs targeted at very small patient populations. It is not uncommon for these products to be priced from $100,000 to $500,000 per annum.
This research reviewed the pricing trends of these unique products, identified the primary characteristics driving these prices and explored alternative payer strategies that have been implement (e.g. outcome contracts) and/or are being proposed (e.g. reimbursement methods).
Methods
A review of publicly available data on unique biopharma products and their pricing was conducted via literature review of PubMed and targeted (non-systematic) internet searches.
Inferences were also drawn from the authors experience and qualitative interviews conducted with key opinion leaders (payers and Biopharma pricing experts).
Conclusions
There are distinctive differences in the approaches to pricing negotiations between payers in the US and Europe. These lead to determinable patterns in the methods that Biopharma companies leverage to price their products and in the methods that payers use, by either working with the biopharma companies or creating reimbursement mechanisms to guide the appropriate utilization of these products.
European payers have more central negotiating leverage, often more formalized health technology assessments, and reference pricing which enable them to negotiate and even mandate prices and/or develop outcome-based contracts.
Unlike European payer, most US payers do not have the support of similar government-backed organizations for negotiating price. This forces US payers to seek more creative ways of managing the appropriate utilization of products through medical policies, increased patient cost sharing, limited usage of formularies, and creative reimbursement methods.
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